ALNY – Alnylam Pharmaceuticals, Inc.
Float Short %
3.3
Margin Of Safety %
-18
Put/Call OI Ratio
0.59
EPS Next Q Diff
-0.81
EPS Last/This Y
7.14
EPS This/Next Y
5.65
Price
430.02
Target Price
503
Analyst Recom
1.81
Performance Q
-10.81
Relative Volume
2.21
Beta
0.31
Ticker: ALNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | ALNY | 441.99 | 0.68 | 0.73 | 35804 |
| 2025-11-11 | ALNY | 451.94 | 0.68 | 1.56 | 35851 |
| 2025-11-12 | ALNY | 452.71 | 0.68 | 0.10 | 35956 |
| 2025-11-13 | ALNY | 453.94 | 0.67 | 0.44 | 36040 |
| 2025-11-14 | ALNY | 448.95 | 0.68 | 1.36 | 36123 |
| 2025-11-17 | ALNY | 460.57 | 0.68 | 1.31 | 36276 |
| 2025-11-18 | ALNY | 462.19 | 0.68 | 1.81 | 36271 |
| 2025-11-19 | ALNY | 460.72 | 0.69 | 0.20 | 36422 |
| 2025-11-20 | ALNY | 445.66 | 0.69 | 0.78 | 36442 |
| 2025-11-21 | ALNY | 436.27 | 0.68 | 1.04 | 36318 |
| 2025-11-24 | ALNY | 434.33 | 0.60 | 1.67 | 28193 |
| 2025-11-25 | ALNY | 429.76 | 0.61 | 0.58 | 28900 |
| 2025-11-26 | ALNY | 445.4 | 0.60 | 0.60 | 29241 |
| 2025-12-01 | ALNY | 454.61 | 0.60 | 1.00 | 29393 |
| 2025-12-02 | ALNY | 465.1 | 0.61 | 0.52 | 29679 |
| 2025-12-03 | ALNY | 473.56 | 0.61 | 0.50 | 29928 |
| 2025-12-04 | ALNY | 465.48 | 0.61 | 0.14 | 31110 |
| 2025-12-05 | ALNY | 458.08 | 0.59 | 0.69 | 32049 |
| 2025-12-08 | ALNY | 429.85 | 0.59 | 0.31 | 33090 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | ALNY | 441.70 | 2542.2 | 677.3 | 4.92 |
| 2025-11-11 | ALNY | 451.95 | 2574.8 | 698.4 | 4.93 |
| 2025-11-12 | ALNY | 452.49 | 2574.8 | 680.2 | 4.93 |
| 2025-11-13 | ALNY | 453.78 | 2574.8 | 681.1 | 4.96 |
| 2025-11-14 | ALNY | 449.08 | 2574.8 | 670.2 | 4.96 |
| 2025-11-17 | ALNY | 460.57 | 2574.8 | 700.2 | 4.96 |
| 2025-11-18 | ALNY | 462.28 | 2574.8 | 682.3 | 4.96 |
| 2025-11-19 | ALNY | 460.76 | 2574.8 | 676.4 | 4.96 |
| 2025-11-20 | ALNY | 446.04 | 2787.9 | 652.7 | 4.96 |
| 2025-11-21 | ALNY | 436.23 | 2787.9 | 661.4 | 4.96 |
| 2025-11-24 | ALNY | 434.41 | 2787.9 | 675.4 | 4.96 |
| 2025-11-25 | ALNY | 429.80 | 2787.9 | 670.7 | 4.96 |
| 2025-11-26 | ALNY | 445.08 | 2787.9 | 708.7 | 4.96 |
| 2025-12-01 | ALNY | 454.64 | 2787.9 | 685.4 | 4.96 |
| 2025-12-02 | ALNY | 464.93 | 2787.9 | 698.1 | 4.96 |
| 2025-12-03 | ALNY | 473.29 | 2787.9 | 694.1 | 4.96 |
| 2025-12-04 | ALNY | 465.48 | 2787.9 | 665.5 | 4.96 |
| 2025-12-05 | ALNY | 458.12 | 2787.9 | 666.3 | 4.96 |
| 2025-12-08 | ALNY | 430.02 | 2787.9 | - | 4.96 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | ALNY | -2.83 | 3.21 | 3.16 |
| 2025-11-11 | ALNY | -2.83 | 3.21 | 3.16 |
| 2025-11-12 | ALNY | -2.83 | 3.21 | 2.98 |
| 2025-11-13 | ALNY | -2.83 | 3.21 | 2.98 |
| 2025-11-14 | ALNY | -3.26 | 3.21 | 2.91 |
| 2025-11-17 | ALNY | -7.09 | 4.92 | 2.91 |
| 2025-11-18 | ALNY | -7.09 | 4.92 | 2.91 |
| 2025-11-19 | ALNY | -7.51 | 4.92 | 2.91 |
| 2025-11-20 | ALNY | -7.12 | 4.92 | 2.91 |
| 2025-11-21 | ALNY | -7.12 | 4.92 | 2.91 |
| 2025-11-24 | ALNY | -7.12 | 2.09 | 2.90 |
| 2025-11-25 | ALNY | -7.45 | 2.09 | 2.90 |
| 2025-11-26 | ALNY | -7.45 | 2.09 | 3.30 |
| 2025-12-01 | ALNY | -7.45 | 2.11 | 3.30 |
| 2025-12-02 | ALNY | -7.45 | 2.11 | 3.30 |
| 2025-12-03 | ALNY | -7.45 | 2.11 | 3.30 |
| 2025-12-04 | ALNY | -5.57 | 2.11 | 3.30 |
| 2025-12-05 | ALNY | -5.57 | 2.11 | 3.30 |
| 2025-12-08 | ALNY | -5.63 | 2.11 | 3.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.9
Avg. EPS Est. Current Quarter
1.73
Avg. EPS Est. Next Quarter
2.09
Insider Transactions
-5.63
Institutional Transactions
2.11
Beta
0.31
Average Sales Estimate Current Quarter
1172
Average Sales Estimate Next Quarter
1223
Fair Value
350.84
Quality Score
73
Growth Score
61
Sentiment Score
82
Actual DrawDown %
13.2
Max Drawdown 5-Year %
-42.5
Target Price
503
P/E
1788.77
Forward P/E
57.13
PEG
P/S
17.7
P/B
242.3
P/Free Cash Flow
256.65
EPS
0.24
Average EPS Est. Cur. Y
4.96
EPS Next Y. (Est.)
10.61
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
1.36
Relative Volume
2.21
Return on Equity vs Sector %
-8.2
Return on Equity vs Industry %
6.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading